Melkie, Addisu (MD, Internist, Nephrologist)Melkeneh, Sirak2021-02-112023-11-052021-02-112023-11-052020-12http://etd.aau.edu.et/handle/123456789/25064Background:Mineral bone disease (MBD) abnormalities are common complications in patients with kidney disease. MBD abnormalities in chronic kidney disease (CKD)patientsare referred to as CKD-MBD; the abnormalities could be biochemical, structural changes of the bone, or both. These abnormalities are known to be associated with increased morbidity and mortality. In spite of their importance, there is limited data on CKD-MBD abnormalities in Ethiopia. This study looked in to the magnitude and factors associated with biochemical CKD-MBD abnormalities among predialysis CKD patients following in a single center in Ethiopia. Objective:The major objective of the study is to determine the magnitude of biochemical mineral bone disease abnormalities; namely, serum calcium, phosphorus and parathyroid hormone levels. Additionally factors associated with these biochemical parameters and the management practices are assessed. Methods: This isa cross-sectional study. One hundred consecutive patients who havehad followup for at least 6 months and eGFRless than 60ml/min/1.73m 2 using CKD- EPI equation were included in this study. Serum calcium, albumin, phosphorusand PTHlevels weredetermined. Demographic and clinical data were collected using a structured questionnaire.IBM SPSS software version26 was used for analysis. Results:The mean age of the patients was 54 with the range of 18 – 92. The male to female ratio is 2.7:1. Patients with stages 3a, 3b, 4 and 5 CKD contributed to 23%, 29%, 26% and 22% of the total respectively. The main causes of CKD were diabetes and hypertension. From the total of 100 patients 31% had hyperphosphatemia,36% hypocalcemia, and 89% had hyperparathyroidism.Estimated GFR correlated negatively with serum PTHlevel but correlated positively with serum calcium level.During a six month follow up period serum calcium and phosphorus were determined at least once in 61% and 62% of patients while serum PTH level wasdetermined in 15% of the patients. Among patients who require treatment according to evidenced based guidelines directed to each biochemical CKD-MBD abnormalities, prescription was given to30% patients for hyperphosphatemia, 38% for those with hypocalcemia, and45% for patients with hyperparathyroidism. Conclusion: Hypocalcemia, hyperparathyroidism, and hyperphosphatemia are common biochemical CKD-MBD abnormalities among predialysis CKD patients following in the renal clinic of TikurAnbessa specialized hospital, Addis Ababa, Ethiopia.en-USBiochemical mineral ,bone disease , predialysis patientsThesis